Adipotide (FTPP): Comprehensive Research Overview

Document Version: 2.0 Last Updated: January 2026 Classification: Research Paper - Experimental Weight Loss Peptides

Goal Relevance:

• Rapid weight loss for obesity management
• Reducing body fat percentage quickly
• Improving body composition by targeting fat cells
• Seeking alternatives to traditional weight loss methods
• Exploring experimental treatments for obesity-related conditions

1. Executive Summary

Overview

Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide), also known as prohibitin-targeting peptide 1, is an experimental peptidomimetic compound designed to selectively induce apoptosis (programmed cell death) in blood vessels supplying white adipose tissue. With the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂ and molecular weight of 2,611.41 g/mol, Adipotide represents a novel approach to obesity treatment through vascular-targeted therapy.

Mechanism: Targeted Adipose Tissue Destruction

The compound consists of two functional domains:

1. Homing Peptide (CKGGRAKDC): Cyclic motif that selectively binds prohibitin receptors on endothelial cells of white adipose tissue vasculature
2. Proapoptotic Domain (D(KLAKLAK)₂): Amphipathic d-enantiomer sequence that disrupts mitochondrial membranes upon receptor-mediated internalization

Result: Blood vessels undergo atrophy and apoptosis, cutting off blood supply to fat cells, causing ischemic injury and subsequent fat cell death.

Preclinical Efficacy: Dramatic Weight Loss in Primates

Treatment with adipotide induced targeted apoptosis within white adipose tissue and resulted in rapid weight loss in obese monkeys:

• Weight Loss: 11% body weight reduction in 28 days
• Body Composition: Marked reduction in white adipose tissue (confirmed by MRI and DEXA)
• Metabolic Benefits: Improved insulin resistance
• Optimal Dose: 0.43 mg/kg daily subcutaneous injection

Human Clinical Trial Failure

Phase 1 Trial (2012-2019):

• Indication: Obesity in patients with metastatic prostate cancer
• Dose: Starting at 0.03 mg/kg daily subcutaneous injection (escalating protocol)
• Outcome: Trial discontinued in January 2019 for unspecified reasons; clinical development permanently abandoned
• Primary Safety Issue: Universal nephrotoxicity

The Fatal Flaw: Kidney Toxicity

The primary side effect is relatively mild, predictable, and reversible renal injury, BUT:

• Universal: ALL treated subjects experienced kidney damage
• Dose-Dependent: Higher doses caused moderate-to-severe tubular degeneration
• Histopathology: Single-cell necrosis, tubular degeneration, regenerative changes
• Biomarkers: Elevated serum creatinine (marker of kidney strain)
• Reversibility: Effects reversed after discontinuation, but required treatment cessation

Critical Problem: The therapeutic window (effective dose vs. toxic dose) was too narrow; weight loss required doses that caused unacceptable kidney damage.

Evidence Quality

• Preclinical Weight Loss (Primates): HIGH - Well-characterized in three monkey species
• Mechanism of Action: HIGH - Prohibitin targeting and apoptosis induction confirmed
• Human Safety: HIGH - Universal nephrotoxicity conclusively demonstrated
• Human Efficacy: UNKNOWN - No published efficacy data from Phase 1 trial
• Long-Term Effects: LOW - Chronic use never studied due to safety termination

Current Status

Adipotide is available as a research chemical for laboratory use only. Despite dramatic preclinical weight loss results, the compound will never be approved for human therapeutic use due to insurmountable kidney toxicity.

2. Goal Archetype Integration

Primary Goal: Targeted Fat Loss

Theoretical Application (NOT RECOMMENDED)

Adipotide was designed for individuals seeking:

• Rapid, significant weight loss in obesity
• Targeted destruction of white adipose tissue
• Visceral fat reduction (abdominal/organ fat)
• Resistance to conventional fat loss methods

Mechanism-Goal Alignment

Why Adipotide Fails for Fat Loss Goals

Despite exceptional efficacy in preclinical studies, Adipotide cannot be recommended for ANY fat loss archetype because:

1. Universal Kidney Damage: 100% of treated subjects experienced nephrotoxicity
2. No Safe Therapeutic Window: Effective fat-loss doses cause unacceptable renal injury
3. Irreversible Mechanism: Fat cell death cannot be reversed if complications arise
4. Clinical Development Abandoned: All human trials terminated for safety reasons

Alternative Compounds for Fat Loss Goals

For individuals seeking targeted fat loss, safer alternatives with established profiles include:

Recommendation: Individuals seeking aggressive fat loss should pursue FDA-approved options (semaglutide, tirzepatide) or well-characterized research peptides (AOD-9604) rather than Adipotide.

3. Age-Stratified Dosing Considerations

Age-Related Kidney Function Considerations

Kidney function naturally declines with age, making older individuals even MORE susceptible to Adipotide-induced nephrotoxicity:

Research Dosing Context (Historical Reference)

Primate Studies (Rhesus Monkeys):

• Dose: 0.43 mg/kg/day subcutaneous
• Duration: 28 days
• Result: 11% weight loss with universal kidney injury

Human Phase I Trial (Terminated):

• Starting Dose: 0.03 mg/kg/day (14x lower than primate effective dose)
• Dose Escalation: Planned but limited by nephrotoxicity
• Population: Adults with metastatic prostate cancer
• Outcome: Trial discontinued due to kidney damage

Why Age Stratification Cannot Mitigate Risk

1. No Dose-Response Safety Window: Even the lowest tested doses caused kidney damage
2. Cumulative Kidney Stress: Older kidneys have less reserve to tolerate injury
3. Comorbidity Burden: Older populations often have hypertension, diabetes, or existing CKD
4. Medication Interactions: Polypharmacy increases nephrotoxic synergy risk
5. Recovery Capacity: Older kidneys have reduced regenerative capacity

Age-Specific Contraindication Summary

Bottom Line: There is no age group for which Adipotide use can be justified. Younger individuals with healthier kidneys still experienced universal nephrotoxicity in trials.

4. Drug Interactions and Renal Toxicity Concerns

High-Risk Drug Interactions (AVOID COMPLETELY)

Category 1: Nephrotoxic Medications

Category 2: Medications Affecting Renal Hemodynamics

Category 3: Supplements and Compounds with Renal Effects

Peptide-Peptide Interactions

Pre-existing Conditions That Contraindicate Adipotide

Interaction Summary

Adipotide should NEVER be combined with:

• Any nephrotoxic medication
• Any medication affecting kidney blood flow
• Any diuretic (risk of dehydration and concentrated toxicity)
• Any other experimental peptide with unknown renal effects

If accidental exposure occurs while on other medications:

• Discontinue Adipotide immediately
• Obtain STAT kidney function tests (BMP, serum creatinine, BUN)
• Urinalysis for proteinuria, hematuria
• Seek immediate medical attention
• Consider nephrology consultation

5. Bloodwork Impact and Kidney Function Monitoring

CRITICAL: MANDATORY KIDNEY MONITORING

If Adipotide exposure occurs (despite all warnings), comprehensive kidney monitoring is ESSENTIAL. Adipotide causes universal nephrotoxicity - the only variable is severity.

Biomarker Changes Observed in Trials

Primary Kidney Function Markers

Urinalysis Markers

Advanced Kidney Injury Biomarkers

Monitoring Protocol (If Exposure Occurs)

Immediate Post-Exposure (First 72 Hours)

Short-Term Monitoring (Days 3-14)

Long-Term Follow-Up (Weeks to Months)

Warning Signs Requiring Immediate Medical Attention

SEEK EMERGENCY CARE IF:

Reversibility of Adipotide-Induced Kidney Damage

Primate Study Findings:

• Kidney damage was described as "relatively mild, predictable, and reversible" after discontinuation
• Recovery occurred over weeks after stopping treatment
• However: This required complete cessation of Adipotide
• Human data: Insufficient to characterize reversibility

Factors Affecting Recovery:

Histopathological Findings (From Primate Studies)

Kidney biopsies in Adipotide-treated primates showed:

1. Single-cell necrosis - Individual cell death in tubules
2. Tubular degeneration - Damage to kidney tubules
3. Regenerative changes - Attempted tissue repair
4. Dose-dependent severity - Higher doses = worse damage

Interpretation: The kidney attempts to repair itself, but the therapeutic dose range causes damage faster than regeneration can occur.

6. Protocol Integration

CRITICAL STATEMENT

Adipotide should NOT be integrated into ANY protocol. Clinical development was permanently terminated due to insurmountable nephrotoxicity. The following information is provided solely for educational purposes regarding why Adipotide cannot be part of a safe protocol.

Why Protocol Integration Is Not Possible

1. No Safe Dosing Window

2. Cannot Be Combined with Other Fat Loss Agents

3. No Supportive Measure Mitigates Toxicity

Theoretical Protocol Structure (FOR EDUCATIONAL REFERENCE ONLY)

This is NOT a recommendation. This represents what was attempted before trials were terminated:

Pre-Treatment Requirements (Historical)

1. Comprehensive metabolic panel with kidney function
2. Baseline eGFR >90 mL/min/1.73m²
3. No pre-existing kidney disease
4. No concurrent nephrotoxic medications
5. Adequate hydration protocol established
6. Nephrology consultation

During Treatment (Historical - Trial Protocol)

• Starting dose: 0.03 mg/kg/day SC (human Phase I)
• Daily kidney monitoring
• Immediate discontinuation at first sign of creatinine elevation
• Aggressive IV hydration to minimize tubular concentration

Post-Treatment (Historical)

• Extended kidney monitoring for 6+ months
• Serial eGFR measurements
• Nephrology follow-up if any abnormalities

Trial Outcome: Despite these precautions, ALL participants experienced kidney damage, and trials were terminated.

Alternative Protocol Recommendations

For individuals seeking aggressive fat loss protocols, consider evidence-based alternatives:

Tier 1: FDA-Approved Options (Strongest Evidence)

Tier 2: Research Peptides with Better Safety Profiles

Tier 3: Combination Approaches (Under Medical Supervision)

• GLP-1 agonist + lifestyle intervention
• GH secretagogue stack + caloric deficit
• AOD-9604 + L-carnitine + exercise

Summary: Why Adipotide Cannot Be Integrated

Final Recommendation: Do not attempt to integrate Adipotide into any fat loss protocol. The compound has been definitively shown to cause kidney damage in all treated subjects, and its clinical development has been permanently abandoned. Pursue safer, evidence-based alternatives for fat loss goals.

7. Chemical Structure & Composition

Chemical Name: Prohibitin-targeting peptide 1 (conjugated to proapoptotic domain) Alternate Names: Adipotide, FTPP (Fat-Targeted Proapoptotic Peptide), Adipotide acetate Amino Acid Sequence: CKGGRAKDC-GG-D(KLAKLAK)₂

• Expanded: Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys—Gly-Gly—(Lys-Leu-Ala-Lys-Leu-Ala-Lys)₂ Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂ Molecular Weight: 2,611.41 g/mol

Structural Domains

1. Prohibitin-Binding Motif (CKGGRAKDC):

• Cyclic peptide (disulfide bond between Cys residues)
• Identified via combinatorial phage display library screening
• Selectively targets prohibitin receptors on adipose tissue endothelium
• Provides tissue specificity (homing function)

2. Linker (GG):

• Diglycine spacer
• Provides flexible connection between functional domains

3. Proapoptotic Domain (D(KLAKLAK)₂):

• D-enantiomer peptide (uses D-amino acids, not natural L-amino acids)
• Sequence: (Lys-Leu-Ala-Lys-Leu-Ala-Lys)₂ (repeated twice)
• Amphipathic structure: alternating hydrophobic (Leu, Ala) and charged (Lys) residues
• Forms α-helix that disrupts mitochondrial membranes
• D-amino acids confer resistance to proteolytic degradation

Mechanism of Action (Detailed)

Step 1: Selective Binding to Adipose Tissue Vasculature

Adipotide binds to two receptors, ANXA2 (annexin A2) and prohibitin, specific to blood vessels supplying white adipose tissue:

• Prohibitin: Mitochondrial chaperone protein aberrantly expressed on endothelial cell surface in adipose tissue
• ANXA2: Cell surface receptor forming complex with prohibitin
• Tissue Specificity: PHB-ANXA2 complex highly expressed in white adipose tissue vasculature; minimal expression elsewhere

Step 2: Receptor-Mediated Endocytosis

After binding, the prohibitin-Adipotide complex undergoes internalization:

1. Receptor-mediated endocytosis
2. Transport to mitochondria via intracellular trafficking
3. Delivery of proapoptotic domain to mitochondrial membranes

Step 3: Mitochondrial Membrane Disruption

The (KLAKLAK)₂ sequence disrupts mitochondrial membranes upon internalization:

• Mechanism: Amphipathic α-helix inserts into mitochondrial membrane
• Outer Membrane Permeabilization: Cytochrome c release
• Inner Membrane Disruption: Loss of mitochondrial membrane potential (ΔΨm)
• Result: Activation of intrinsic apoptosis pathway

Step 4: Endothelial Cell Apoptosis

Mitochondrial disruption triggers apoptosis cascade:

1. Cytochrome c → caspase-9 activation
2. Caspase-9 → effector caspase-3/7 activation
3. Caspase-mediated DNA fragmentation and cellular dismantling
4. Endothelial cell death

Step 5: Vascular Atrophy and Adipocyte Death

Blood vessels undergo atrophy (shrinkage) and eventually apoptosis, cutting off blood supply to fat cells:

• Vascular Regression: Loss of capillary network in adipose tissue
• Ischemic Injury: Lack of oxygen/nutrients to adipocytes
• Adipocyte Apoptosis: Fat cells undergo programmed cell death
• Irreversibility: Effects are non-reversible; fat cells permanently destroyed

Step 6: Systemic Weight Loss

Dead adipocytes are cleared by macrophages, resulting in:

• Reduction in white adipose tissue mass
• Decreased body weight (11% in 28 days in monkeys)
• Improved insulin sensitivity (reduced adiposity → enhanced glucose metabolism)

8. Dosing Reference (Historical - Trial Data Only)

Primate Studies (Research Context)

Human Phase I Trial (Terminated)

• Starting Dose: 0.03 mg/kg daily subcutaneous injection
• Protocol: Dose escalation planned but limited by safety concerns
• Outcome: Trial discontinued due to nephrotoxicity
• Status: Clinical development permanently abandoned (January 2019)

Safety Profile Summary

• Kidney Toxicity: Universal - ALL treated subjects experienced renal injury
• Histopathology: Tubular degeneration, single-cell necrosis, regenerative changes
• Biomarkers: Elevated serum creatinine (dose-dependent)
• Reversibility: Effects reversed after discontinuation, but required stopping treatment
• Conclusion: No safe therapeutic window identified

10. Product Cross-Reference

Core Peptides Product:

• Size: 10 mg
• Price: $78.00 (bulk discounts: 5-8 units 5% off, 9+ units 10% off)
• Purity: >99%
• Form: Lyophilized powder
• Note: "For research use only - not for human consumption"

11. References & Citations

1. Prohibitin-targeting peptide 1 - Wikipedia
2. Peptidomimetic Targeting White Fat in Obese Monkeys - PMC
3. Adipotide Patient Outcomes - Peptide Initiative
4. Adipotide Side Effects - PEP DOSE
5. Adipotide: Targeted Peptide Research - RightPatient
6. Peptide Designed to Elicit Apoptosis - PMC
7. Adipotide Obesity Drug Clinical Trials - DietsinReview
8. Adipotide (FTPP) and Fat Cells - Biotech Peptides
9. Obese Monkeys Lose Weight - MD Anderson

12. Summary and Final Assessment

Key Takeaways

Why Adipotide Represents a Failed Drug Development

1. The Fundamental Problem: Effective fat loss required doses that inevitably caused kidney damage
2. No Solution Found: Neither dose reduction nor supportive measures prevented nephrotoxicity
3. Therapeutic Index: Zero - there is no dose that is both effective AND safe
4. Irreversible Action: The vascular destruction mechanism cannot be stopped once initiated

For Individuals Seeking Fat Loss

Do NOT consider Adipotide. Instead, consult with healthcare providers about:

• FDA-approved options: Semaglutide (Wegovy, Ozempic), Tirzepatide (Mounjaro, Zepbound)
• Research peptides with better safety: AOD-9604 (excellent safety, modest efficacy)
• Lifestyle interventions: Diet, exercise, behavioral modification
• Medical supervision: Weight management programs with monitoring

Final Warning

Adipotide is one of the clearest examples in peptide research of a compound with exceptional efficacy that cannot be developed due to insurmountable safety concerns. Despite achieving dramatic weight loss in preclinical studies, the universal kidney toxicity makes it unsuitable for human use at any dose.

This compound should never be used for weight loss. The risk of permanent kidney damage is not justified by any potential benefit.

Document Prepared By: Research Team, DosingIQ Intended Use: Educational and research reference Disclaimer: Adipotide is NOT approved for human use and causes universal kidney toxicity. This compound is extremely dangerous and should never be used for weight loss. For research purposes only.